

Overview of HL7 FHIR Accelerator Vulcan, for Bringing Interoperability to Clinical Research

Presented at CDISC Japan Interchange, June 12, 2024



Meet the Speaker

Mika Ogasawara

Title: Overview of HL7 FHIR Accelerator Vulcan, for Bringing Interoperability to Clinical Research

Organization: Pfizer R&D Japan, representing HL7 Vulcan

Currently working for Biometrics & DM, Pfizer R&D Japan as the Data Quality Lead and having been assigned as a member of the HL7 Vulcan Operation Committee by Pfizer since its activity started in 2020. She is also a member of Japan Operational Committee of TransCelerate Pharma Inc, especially in charge of engaging Process Harmonization program (i.e, Digital Data Flow, eSource, etc.

As a part of her responsibilities in Pfizer, she is leading eSource project in Japan as a part of global eSource program. She has over 25 years' experience in Pharmaceutical industry and mostly served data management and clinical study data related activities.



- The views and opinions expressed in this presentation are those of the author(s) and do not necessarily reflect the official policy or position of CDISC.
- There is no financial relationship or conflict of interest relevant to this presentation
- The author has no real or apparent conflicts of interest to report.



Agenda

- 1. HL7 FHIR background
- 2. Vulcan background
- 3. Vulcan Use Cases (Projects)
 - Overall
 - Featuring a couple of projects

Special thanks to

Vulcan core members



What is HL7 FHIR?



FHIR, or Fast Healthcare Interoperability Resources, is an international Standard for exchanging healthcare information electronically in a consistent fashion.

FHIR R4 is the modernization of and best feature reutilization from HL7's v2, v3, and CDA products. It's also an evolving set of resources that can be expressed as an **80/20 rule**, where 80% is a common starting point and the remaining 20% are in the form of specialized use cases based on third-party extensions.

FHIR aims to simplify implementation without sacrificing information integrity. It leverages existing logical and theoretical models to provide a consistent, easy to implement, and rigorous mechanism for exchanging data between healthcare applications.

Why?	Interoperability out-of-the-box (bridge clinical research and clinical care)
How?	Built on web standards (e.g., XML, JSON, HTTP, and Oauth)
What?	Flexible standard with 150+ resources to cover a wide array of use cases
Who?	Diverse global community (hospitals, academia, vendors, biopharma, regulators)

Source: https://www.hl7.org/fhir/overview.html, https://www.healthit.gov/sites/default/files/2019-08/ONCEHIRESWhatIsEHIR.pdf, R4 is the current version of the FHIR standard





Interoperability

Interoperability is the ability of computer systems, devices or software to exchange and use data seamlessly, by design.

Electrical power is a great example:


- generated by multiple sources
- distributed in standard ways
- used by simply plugging in





Vulcan and the HL7 FHIR® Ecosystem

........



Founded in 1987, Health Level Seven[®] International (HL7) is an ANSI-accredited, not-for-profit standards developing organization with the mission of empowering global health interoperability. With affiliates in over 30 countries, HL7's global membership envisions a world in which everyone can securely access and use the right data when and where they need it.

The HL7 FHIR ACCELERATOR program is designed to assist communities and collaborative groups across the global health care spectrum in the creation and adoption of high quality FHIR Implementation Guides or other standard artifacts to move toward the realization of global health data interoperability.

Vulcan aims to serve a user community focused on integrating clinical research and clinical care through the adoption of FHIR.



Vulcan HL7 FHIR Accelerator Accelerating Interoperability in Clinical Research

Vulcan is a diverse and global research community collaborating to align care and clinical & translational research by driving standards-based exchange of health and research data.







Vulcan – Moving Forward Inflection Point









Vulcan Accomplishments - Highlights

- 3 Projects complete and Implementation Guide Published (RWD, SoA, ePI)
- 1 Project nearing complete (AE)
- 2 Projects Ongoing (Phenotypic data, FHIR to OMOP)
- 3 Projects in Discovery (Sample data, UDP, ACTR)
- Track at every connectathon since Jan 2021 (nearly 30 tracks on 7 topics)
- Large and small events organised
 - Vulcan 101 (multiple)
 - EuroVulcan (x2)
 - Implementation Showcase (multiple)
 - Conference presentations / presence (MIE, JAMI, FHIR DevDays, etc.)



Vulcan HL7 FHIR® Accelerator **Projects at-a-glance**



Objectives Vulcan Leads Represent the schedule of activities in FHIR from a *Mike Ward* (TransCelerate) spreadsheet. Enable the consistent description, timing and **Geoff Low** (PHUSE) identification of each activity in a study Extract data from EHRs in a standardized format to support Scott Gordon (FDA) clinical research and especially submission to Regulators Alex Cheng (Vanderbilt) **Phenomics Exchange for Research** To increase the availability of high-quality standardized Anita Walden (University of phenotypic information for genomic research and genomic Colorado Anshutz) medicine. Shahim Essaid (University of Colorado Anschutz) Define a common structure for product information (monographs) Craig Anderson (Pfizer)

Has an IG published

Electronic Product Information (ePI) that supports cross-border exchange of data for patients Catherine Chronaki (Secretary General at HL7 Europe) **Adverse Events (AE)** Support standardizing the reporting and format of an adverse Michelle Casagni (MITRE) event. Improve the maturity of the relevant FHIR resources Ed Millikan (FDA) FHIR to OMOP Support the development of FHIR to OMOP data transfer for Davera Gabriel (Evidentli) better analysis of clinical data for research

Sample Data Provide sets of data suitable for use in testing Vulcan Catherine Craven (Independent, applications and implementation guides SME) Russell Leftwich (InterSystems) Some data sets to be wholly synthetic, others to be anonymized real data



Project


Schedule of Activities (SoA)

Real World Data (RWD)

and **Diagnostics**




ICH M11 and Vulcan Utilizing Digital Protocol



Inputs: ICH M11 template ICH M11 technical specification Models, definitions FHIR will carry CDISC CT and USDM content The technical

specification can be used to develop other Implementation Guides




CDISC 2024 Japan Interchange | #ClearDataClearImpact


Design Layers – House Building

Constraint

Increasing



Digital Protocol





Implementation Guides are Key



FHIR Resources (components – like Lego blocks)

- Open Source No membership required
- FHIR makes no assumptions about the architectural design of systems
- The content is the same structure whatever the interoperability paradigm



Implementation Guides





Data Transport Models – (the finished Lego structure)







Example Vulcan Implementation Guide

Image: Health Level Seven Internation X

 HLT.FHIR.UVXULCAN-SCHED X

 All HIT.FHIR.UVXULCAN-SCHED X

 Bunch X
<td

Clinical Study Schedule of Activites, published by HL7 International - Biomedical Research & Regulation Work Group. This is not an authorized publication; it is the continuous build for version 1.0.0-ballot). This version is based on the urrent content of https://github.com/HL27Noilcas-Abeiluble.jng/ and changes regularly. See the Directory of

1 Home

Official URL: http://hl7.org/fhir/uv/vulcan- schedule/ImplementationGuide/hl7.fhir.uv.vulcan-schedule	Version: 1.0.0-ballot
Draft as of 2022-12-04	Computable Name: StudyScheduleOfActivities

1.1 Background

1.1.1 Vulcan Schedule of Activities (SoA) Project

The core of this project is to define a usable pattern for a Clinical Trial Schedule of Activities structure using FHIR Resources and Processes, such that:

it can be shared

.......

- it can be interpreted, and
- · it can be implemented in healthcare systems (such as EHR or PHR systems) and/or clinical research systems

The conduct of Clinical Trials are guided by the International Conference on Harmonization (ICH) guidelines for Good Clinical Practice (GCP) E6 (R2): Core to this is the writing of a Clinical Trial Protocol, a document intended to describe the objectives, design, methodology, statistical considerations and aspects related to the organization of the clinical trial.


Trial protocols provide the background and rationale for conducting a study, highlighting specific research questions that are addressed, and taking into consideration ethical issues. Trial protocos must meet a standard that adhress to the principles of Good Clinical Practice (as mentioned above), and are used to obtain ethics approval by local Ethics Committees or Institutional Review Boards.

The Clinical Trial Protocol incorporates all the aspects of what is needed to define how the study is to be conducted and reviewed; for the purposes of this first iteration of the Implementation Guide we are constraining the scope to focus just on the elements incorporated in the Schedule of Activities.

1.1.2 What is the Schedule of Activities?

The NCI Controlled Vocabulary definition of the Schedule of Activities is: 2

A standardized representation of planned clinical trial activities including interventions (e.g., administering drug_surgery) and study administrative activities (e.g., obtaining informed consent, distributing clinical trial




Search: Vulcan-schedule-ig


CDISC 2024 Japan Interchange | #ClearDataClearImpact

........ **Development Timeline**





CDISC 2024 Japan Interchange | #ClearDataClearImpact



THE WHITE HOUSE

The White House Office of Science & Technology Policy (OSTP) Announcement

OCTOBER 26. 2023 A Stronger Clinical Trial Infrastructure for Better Health Outcomes

. OSTP + NEWS & UPDATES + OSTP BLOG

By Grail Sipes, Assistant Director for Biomedical Regulatory Policy, White House Office of Science and Technology Policy

Testing medical interventions through clinical trials is an essential part of creating and delivering effective health care for everyone in America. Strengthening our clinical trials infrastructure will help us improve health outcomes, and will drive forward the Biden Cancer Moonshot goal to end cancer as we know it. <u>"Vulcan</u>, together with <u>CodeX</u> and others, is stepping up to speed the development of standardized approaches to data exchange, with the goal of piloting faster and more inclusive data capture for multi-site clinical trials."



🛃 VULCÁN

OSTP Blog Announcement – What Does it Mean for Vulcan?



- Existing Vulcan IG's and ongoing projects can be leveraged to reach these goals:
 - ✓ Adverse Events for clinical research (AE)
 - ✓ Real world Data (RWD)
 - ✓ UDP
- Development of new open standards is envisaged e.g. Modular Protocols
- Testing and demonstration is key Vulcan can enable this through Connectathons and Reference Implementations
- It will generate momentum that matches Vulcan objectives
- US developments often travel the world Vulcan can be the messenger through its global network and membership





Get Involved!



To learn more or to get involved



Visit our website http://www.hl7.org/vulcan/



Visit our confluence page https://confluence.hl7.org/display/VA/Vulcan+Accelerator+Home



Email us at Vulcan@HL7.org





Thank You!

